These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31185957)

  • 1. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival.
    Morganti AG; Cellini F; Buwenge M; Arcelli A; Alfieri S; Calvo FA; Casadei R; Cilla S; Deodato F; Di Gioia G; Di Marco M; Fuccio L; Bertini F; Guido A; Herman JM; Macchia G; Maidment BW; Miller RC; Minni F; Passoni P; Valentini C; Re A; Regine WF; Reni M; Falconi M; Valentini V; Mattiucci GC
    BMC Cancer; 2019 Jun; 19(1):569. PubMed ID: 31185957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
    Golden DW; Novak CJ; Minsky BD; Liauw SL
    Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
    Morganti AG; Falconi M; van Stiphout RG; Mattiucci GC; Alfieri S; Calvo FA; Dubois JB; Fastner G; Herman JM; Maidment BW; Miller RC; Regine WF; Reni M; Sharma NK; Ippolito E; Valentini V
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):911-7. PubMed ID: 25220717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
    Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
    Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
    Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
    HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
    Tomihara H; Eguchi H; Yamada D; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Surg Today; 2017 Feb; 47(2):218-226. PubMed ID: 27586014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
    Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE
    World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control.
    Wo JY; Childs SK; Szymonifka J; Mamon HJ; Ryan DP; Blaszkowsky LS; Kwak EL; Ferrone CR; Allen JN; Zhu AX; Wolpin BM; Chan JA; Abrams TA; McCleary NJ; Fernandez-Del Castillo C; Hong TS
    Pract Radiat Oncol; 2014; 4(2):e117-e123. PubMed ID: 24890357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection.
    Naffouje SA; Sabesan A; Kim DW; Carballido E; Frakes J; Hodul P; Denbo JW; Malafa M; Fleming J; Hoffe S
    J Gastrointest Surg; 2022 Feb; 26(2):376-386. PubMed ID: 34506031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer.
    Ma SJ; Prezzano KM; Hermann GM; Singh AK
    Radiat Oncol; 2018 Nov; 13(1):214. PubMed ID: 30400962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
    Habermehl D; Kessel K; Welzel T; Hof H; Abdollahi A; Bergmann F; Rieken S; Weitz J; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
    Radiat Oncol; 2012 Mar; 7():28. PubMed ID: 22385572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
    Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
    Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
    Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
    Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.